Investment Rating - The report suggests a focus on Haisheng Medical as a leading player in the anesthesia and monitoring medical device sector, recommending attention to the company [4][5]. Core Insights - Haisheng Medical is set to issue shares at a price of 12.64 CNY per share with an initial issuance of 11.29 million shares, representing 15% of the total post-issue share capital [4][7]. - The company has a projected total investment of 482.7 million CNY for its fundraising projects, primarily aimed at upgrading and automating its anesthesia monitoring emergency medical devices [4][10]. - The company reported a net profit of 58.78 million CNY for Q1-Q3 2025, reflecting a year-on-year increase of 26.70% [4][12]. - The global low-value consumables market is expected to grow steadily, potentially reaching 129.82 billion USD by 2030, with the Chinese market for low-value medical consumables projected to reach 221.3 billion CNY by 2025 [4][14][18]. Company Overview - Haisheng Medical, established in 2000, specializes in anesthesia and monitoring medical devices, achieving a net profit of 78.04 million CNY in 2023, a year-on-year increase of 11% [4][12]. - The company has developed a comprehensive product matrix covering eight major series, including airway and respiratory management, life information monitoring, and nerve block products [4][14]. - As of November 13, 2025, the company holds 63 national authorized patents, including 13 invention patents, and has 53 medical device registrations [4][14]. Market Potential - The global medical device market is projected to grow from 479.36 billion USD in 2023 to 637.96 billion USD by 2028, with China's medical device market expected to reach 1.66 trillion CNY by 2030 [4][14]. - The demand for low-value medical consumables in China is anticipated to grow rapidly, with the market size expected to reach 221.3 billion CNY in 2025 [4][18]. Subscription Recommendation - Haisheng Medical is positioned as a leading supplier in the anesthesia and monitoring medical device sector, with a strong focus on product quality and continuous technological innovation [4][12].

Core Viewpoint - Zhejiang Haisheng Medical Equipment Co., Ltd. is preparing for an IPO on the Beijing Stock Exchange, focusing on the development, production, and sales of anesthesia and monitoring medical devices, with a significant market presence and a gross margin exceeding 50% [1][2]. Financial Performance - The company reported net profits attributable to the parent company of 75.11 million yuan and 68.04 million yuan for 2023 and 2024, respectively [2]. - Total assets increased from 319.68 million yuan in 2022 to 519.45 million yuan by June 30, 2025, indicating a growth trend [3]. - The company's gross margin for the reporting periods was consistently above 50%, with specific figures of 52.84%, 53.15%, 52.07%, and 51.56% [4]. Sales and Revenue - The company’s sales revenue from anesthesia consumables and monitoring products accounted for 48.51% and 38.80% of total revenue in the respective periods [3]. - The sales revenue from the "two-invoice system" was relatively low, contributing only 2.78% to 3.30% of total revenue across the reporting periods [8]. - Concentrated procurement sales revenue was 30.30 million yuan, 34.88 million yuan, and 46.88 million yuan for the years 2023, 2024, and 2025, respectively, representing 11.34% to 16.20% of total revenue [8]. Inventory and Accounts Receivable - The company's inventory value increased from 52.63 million yuan in 2022 to 41.64 million yuan in 2025, reflecting an upward trend as the business scales [5]. - Accounts receivable also rose, indicating a potential for sustained revenue growth, with values of 24.85 million yuan in 2022 and 32.88 million yuan in 2025 [5]. Research and Development - The company is investing in R&D for new medical devices, with ongoing projects for a research and marketing service base and headquarters, with a budget of 243 million yuan [6][7]. Customer Base and Distribution - The company relies heavily on a network of distributors, with 90.43% of revenue coming from distribution sales, and has a total of 919 distributors [13]. - The largest customer, Guangzhou Rongsheng Medical Equipment Co., Ltd., accounted for 8.09% of total revenue in the first half of 2025, indicating a concentration risk [13]. Sales Expenses - Sales expenses as a percentage of revenue were higher than the industry average, at 10.63% in the first half of 2025, compared to an average of 6.25% for comparable companies [16][17]. - The company’s sales expenses are primarily driven by employee compensation, promotional activities, and travel expenses [16]. Regulatory Environment - The impact of policies such as "two-invoice system" and "centralized procurement" on the company's operations is limited, as the company primarily deals with low-value medical devices [8][12].

Core Viewpoint - Haiseng Medical's IPO journey faces significant challenges despite a 26.70% year-on-year profit increase to 58.78 million yuan in the first three quarters of 2025, with concerns over its weak position in the supply chain and unstable performance [1] Supply Chain Vulnerabilities - Raw material costs account for over 60% of production costs, with a dependency on Israeli supplier Elcam Medical reaching 19.26% [2] - As of the first half of 2025, 10.44% of key components were still imported, indicating potential risks to production continuity [2] - The self-manufacturing ratio for infusion valves was only 7.24%, with no disclosed capacity assurance agreements from alternative suppliers [2] Research and Development Challenges - R&D investment has been insufficient, with expenses rising from 13.54 million yuan in 2022 to 16.16 million yuan in 2024, maintaining a revenue ratio of 5%-6% [2] - Compared to peers like Weili Medical, which spent 111 million yuan on R&D in 2024, Haiseng's investment is significantly lower [2] - Of the 63 patents held, only 13 are invention patents, and none of the nine ongoing projects have reached advanced clinical stages [2] Sales Channel Instability - The sales channel is heavily reliant on domestic distributors, with distributor revenue accounting for 83.16%-90.43% during the reporting period [3] - A high turnover rate of distributors was noted, with over 50% changes in the last two years [3] - The gross margin of exiting distributors was 58.95%, higher than the overall company level, indicating issues with distributor management [3] Impact of Procurement Policies - Revenue from centralized procurement products increased from 30.30 million yuan to 46.88 million yuan, rising from 11.34% to 15.45% of total revenue [3] - Price pressures from procurement policies have led to a decline in gross margins, with the gross margin for centralized procurement products dropping from 48.71% in 2022 to 46.49% in 2024 [3] Financial Performance Fluctuations - In 2024, revenue decreased by 0.7% to 304 million yuan, with a 9.41% drop in net profit attributable to the parent company [5] - Despite maintaining a gross margin around 52%, structural risks are evident, particularly with domestic distributor margins declining [5] - Sales expenses rose from 9.48% to 10.76%, significantly exceeding R&D expenses, indicating a reliance on high marketing costs [5] Capacity Expansion Concerns - The 370 million yuan fundraising plan has raised doubts, with 174 million yuan allocated for expanding production capacity by 60% [6] - Core product capacity utilization rates have declined, raising questions about the rationale behind expanding capacity [6] - The company faces challenges in channel absorption, with 5.63% of revenue coming from exited distributors [6] Systemic Risks and Regulatory Challenges - The inclusion of low-value consumables in centralized procurement could further pressure profit margins, potentially lowering the gross margin below 52% [7] - The expiration of CE certification poses risks for EU market access, with a deadline for compliance with new MDR regulations by 2028 [7] - The uncertainty surrounding high-tech enterprise qualifications and R&D expense rates adds to the challenges faced by the company [7]